Ann: Permetrex Outperforms Other CBD Topical Products, page-58

My point is that what are in fact conclusions are presented as aims right after "Botanix commissioned a leading US skin testing laboratory ...", and although I doubt that the lab was asked/required to come to the desired conclusion, the juxtaposition does not look very elegant to me, and nor do "fail to live up to" and "fail to deliver". I also think Botanix needs to very confident of what constitutes a therapeutically effective amount of CBD and should have worked harder to produce a suitably bland statement which nevertheless gets the points across.

While some in Botanix may believe that the share price is sitting around 10 cents because insufficient noise has been made about its achievements there are others, including myself, who point to other reasons the company is in a state of being "sold short" - one being share fire-sales and associated manoeuvres.

So I will be blunt: my take is that Marketing (in its widest sense) needs to be kept under closer control and the crown jewels need to be more carefully displayed and more closely guarded.